Public notice

No. Title Writer Date Inquiry
9 (주)아이비스바이오 임시 주주 총회
관리자 23.10.13 Inquiry : 419
관리자 23.10.13 419
8 A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
관리자 23.05.19 Inquiry : 575
관리자 23.05.19 575
7 Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury
관리자 23.01.17 Inquiry : 665
관리자 23.01.17 665
6 3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation
관리자 23.01.17 Inquiry : 608
관리자 23.01.17 608
5 Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.
관리자 23.01.17 Inquiry : 636
관리자 23.01.17 636
4 Researches on immunomodulatory imides drug development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Int J Mol Sci. (July 31, 2021).
관리자 23.01.17 Inquiry : 678
관리자 23.01.17 678
3 The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS P
관리자 23.01.17 Inquiry : 639
관리자 23.01.17 639
2 Research on the immunomodulatory imide drugs development under the Cooperative Research and Development Agreement(CRADA) with the National Institutes of Health(NIH) have been published in the peer-reviewed publication, Frontiers in Neuroscience(March 2)
관리자 23.01.17 Inquiry : 602
관리자 23.01.17 602
1 The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife
관리자 23.01.17 Inquiry : 591
관리자 23.01.17 591